News
Rapid Solid-State Screening
For pharmaceutical and biotechnology companies, it is important to identify as many polymorphic forms of a small molecule therapeutic as possible, to mitigate threats from competitors and to create opportunities to optimise product performance.
Particle Engineering to Optimise the Performance of Inhaled Therapeutics
The Crystec mSAS® (modified supercritical anti-solvent) process offers distinct advantages in the development of high-performing inhaled products.
Crystec at #CPhI2023
Meet with the Crystec team at CPhI2023 in Barcelona to explore how we can transform the performance of medicines together.
Next-Generation Biomanufacturing
mSAS® supercritical fluid technology marks a significant step forward in the stabilisation and processing of biomolecules.
Meet Crystec at BIO2023
Exciting times ahead at #BIO2023 in Boston! Join us as we bring together the brightest minds in biotechnology to discuss the latest breakthroughs and innovations. Don’t miss this opportunity to network, learn, and collaborate.
BioNow Technical Service of the Year Award 2022
We are delighted to announce that we have been shortlisted for the BioNow Technical Service of the Year Award 2022. The submission, ‘mSAS® – revolutionising the speed and efficiency of biomolecule product development’, encompasses the significant advances that we have made in this area, and are now able to routinely offer to our clients.
Therapeutic Area Partnerships: Accelerating Innovation in Women’s Health
CrystecPharma recently attended, and presented at, the first edition of Therapeutic Area Partnerships: Accelerating Innovation in Women’s Health, a digital conference delivered by Informa Connect.
A collaboration to enhance the delivery of biotherapeutics
19th October 2021. Crystec Ltd. and Biosidus S.A. are delighted to announce their collaboration focused on enhancing the delivery and performance of biotherapeutics.
